Hot Features
Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. It also engages in the ... Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addition, the company develops DCVax-Direct in Phase I trials to treat inoperable solid tumors. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.00609 | -3.15707620529 | 0.1929 | 0.2362 | 0.18 | 3932555 | 0.18851822 | CS |
| 4 | -0.03449 | -15.5851784907 | 0.2213 | 0.2362 | 0.18 | 2751651 | 0.1937646 | CS |
| 12 | -0.01609 | -7.93001478561 | 0.2029 | 0.2999 | 0.18 | 3335889 | 0.21192012 | CS |
| 26 | -0.03819 | -16.9733333333 | 0.225 | 0.3389 | 0.18 | 3020852 | 0.23200488 | CS |
| 52 | -0.06519 | -25.869047619 | 0.252 | 0.368 | 0.18 | 3119910 | 0.24076174 | CS |
| 156 | -0.40309 | -68.3319206645 | 0.5899 | 1.11 | 0.16845 | 2642239 | 0.35355956 | CS |
| 260 | -1.27319 | -87.2047945205 | 1.46 | 2.05 | 0.16845 | 2454196 | 0.5362386 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.